>Bionic eye with better sight
The world's first 3D artificial eyeball - capable of outperforming the human eye in some ways - may help droves of people who are partially or fully blind in five years, according to experts.
Researchers from Hong Kong University of Science and Technology have devised an electrochemical eye whose structure and performance mimic those of the ones humans are born with.
"The device design has a high degree of structural similarity to a human eye with the potential to achieve high imaging resolution when individual nanowires are electrically addressed," researchers of Hong Kong University of Science and Technology wrote in a paper published in the journal Nature.
Aside from helping individuals improve their vision, experts claim the technology may help create biomimetic photosensing devices that could be used in a "wide spectrum of technological applications."
>Lego unveils Monkey King set
Following popular Western film and television works such as Harry Potter and Star Wars, the Monkey King from the classic Chinese novel "Journey to the West" has become the first Chinese hero to get his own Lego model.
The Lego company launched Monkie Kid, its first series based on Chinese culture, in Shanghai on May 15.
The series created by a Chinese team consists of eight play sets and an animated film.
Based on the story of the Monkey King in "Journey to the West", the series introduces a new character, Monkie Kid, who is a young noodle shop delivery boy.
The introduction on the company's official website says that Monkie Kid finds himself and his friends entangled in adventures full of action, mystery and magic as they fight the Bull Demon King with the help of the Monkey King's golden bar.
After gathering sales data, the staff at Lego found that Chinese elements have been increasingly accepted by consumers in Western countries.
>Vaccine trial promising
The first COVID-19 vaccine to undergo a clinical trial in China has been found to be safe and able to generate an immune response against the novel coronavirus in humans, based on the results of a preliminary trial, according to research published on Friday night in the medical journal The Lancet.
The phase-one clinical trial of the vaccine involving 108 healthy adults, which lasted 28 days, showed promising results, although further trials are required to determine whether the immune response it elicits can effectively protect humans against novel coronavirus infection, according to the researchers of the vaccine.
"The trial demonstrates that a single dose of the vaccine produces virus-specific antibodies in 14 days, making it a potential candidate for further investigation," said Chen Wei from the Beijing Institute of Biotechnology, a leading researcher in the study.
"However, these results should be interpreted cautiously. "
"The challenges in the development of a COVID-19 vaccine are unprecedented, and the ability to trigger these immune responses does not necessarily indicate that the vaccine will protect humans from COVID-19. "
"We are still a long way from this vaccine being available to all."
>US COVID-19 dead near 100,000
The front page of Sunday's New York Times features the names of 1,000 people who have died of COVID-19 in the US.
Calling it "an incalculable loss", the newspaper clarified that "the 1,000 people here reflect just 1% of the toll".
"They were not simply names on a list. They were us," the paper said.
"Numbers alone cannot possibly measure the impact of the coronavirus in America, whether it is the number of patients treated, jobs interrupted or lives cut short."
Over 96,000 people have died of the coronavirus in the US, the largest toll among all the countries in the world, according to the Center of Systems Science and Engineering of Johns Hopkins University as of Sunday morning.
Find more audio news on the China Daily app.